The potential use of biomarkers in predicting contrast-induced acute kidney injury.

Abstract

Contrast-induced acute kidney injury (CI-AKI) is a problem associated with the use of iodinated contrast media, causing kidney dysfunction in patients with preexisting renal failure. It accounts for 12% of all hospital-acquired kidney failure and increases the length of hospitalization, a situation that is worsening with increasing numbers of patients with comorbidities, including those requiring cardiovascular interventional procedures. So far, its diagnosis has relied upon the rise in creatinine levels, which is a late marker of kidney damage and is believed to be inadequate. Therefore, there is an urgent need for biomarkers that can detect CI-AKI sooner and more reliably. In recent years, many new biomarkers have been characterized for AKI, and these are discussed particularly with their use in known CI-AKI models and studies and include neutrophil gelatinase-associated lipocalin, cystatin C (Cys-C), kidney injury molecule-1, interleukin-18, N-acetyl-β-d-glucosaminidase, and L-type fatty acid-binding protein (L-FABP). The potential of miRNA and metabolomic technology is also mentioned. Early detection of CI-AKI may lead to early intervention and therefore improve patient outcome, and in future any one or a combination of several of these markers together with development in technology for their analysis may prove effective in this respect.

• Authors: Michele Andreucci, Teresa Faga, Eleonora Riccio, Massimo Sabbatini, Antonio Pisani, Ashour Michael
• Journal: International journal of nephrology and renovascular disease (Int J Nephrol Renovasc Dis) Vol. 9 Pg. 205-21 ( 2016) ISSN: 1178-7058 [Print] New Zealand
• PMID: 27672338 (Publication Type: Journal Article, Review)